Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
5,120.00
+195.00 (3.96%)
Feb 18, 2025, 9:00 AM KST
Bukwang Pharmaceutical Revenue
Bukwang Pharmaceutical had revenue of 42.60B KRW in the quarter ending September 30, 2024, with 110.33% growth. This brings the company's revenue in the last twelve months to 138.93B, down -14.45% year-over-year. In the year 2023, Bukwang Pharmaceutical had annual revenue of 125.93B, down -34.04%.
Revenue (ttm)
138.93B
Revenue Growth
-14.45%
P/S Ratio
2.45
Revenue / Employee
250.77M
Employees
554
Market Cap
340.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 125.93B | -64.98B | -34.04% |
Dec 31, 2022 | 190.91B | 8.42B | 4.61% |
Dec 31, 2021 | 182.49B | 12.83B | 7.56% |
Dec 31, 2020 | 169.66B | 1.47B | 0.87% |
Dec 31, 2019 | 168.19B | -26.03B | -13.40% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,495.50B |
Peptron | 2.41B |
Hanall Biopharma | 134.24B |